Linked Life Data

15579103

Source:http://linkedlifedata.com/resource/pubmed/id/15579103

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
16
pubmed:dateCreated
2004-12-6
pubmed:abstractText
The P2X(7) receptor is involved in several processes relevant to inflammation (cytokine release, NO generation, killing of intracellular pathogens, cytotoxicity), thus, it may be an appealing target for pharmacological intervention. The characterisation of native and recombinant P2X(7) receptor continues to be hindered by the lack of specific and subtype-selective agonists and antagonists. BzATP is currently the most potent agonist known at the endogenous and recombinant P2X(7) receptor A tyrosine derivative named KN-62 exhibits selective P2X(7) receptor-blocking properties. In this review article we have reported novel series of KN-62-related compounds of the general structure R(1)-Tyr(OR(2))-piperazinyl-R(3), in which three positions (R(1), R(2) and R(3)) were systematically varied. Two recent articles published by AstraZeneca have reported that novel series of cyclic imides and adamantane amides are potent P2X(7) receptor antagonists.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1568-0266
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1707-17
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Agonists and antagonists acting at P2X7 receptor.
pubmed:affiliation
Dipartimento di Scienze Farmaceutiche, Universita di Ferrara, Via Fossato di Mortara 17-19, 44100-Ferrara, Italy. pgb@ifeuniv.unife.it
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't